ERBB2 and breast cancer: In agreement with these findings, our recent characterization of the immune profile of 61 locally advanced BC patients eligible for a NC schedule demonstrated that, at diagnosis, patients with HER2-overexpressing cancers had a retained immune proficiency and higher CD8+ T cell responses against several TAAs if compared to HER2-negative cases, whose general immune background, on the contrary, appeared compromised [23].